

Clin Exp Vaccine Res 2023;12:176-178 https://doi.org/10.7774/cevr.2023.12.2.176 pISSN 2287-3651 • eISSN 2287-366X

Astrid Herzum, Corrado Occella, Ehab Garibeh, Lodovica Gariazzo, Gianmaria Viglizzo

Dermatology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy

Received: February 3, 2023 Accepted: March 31, 2023

Corresponding author: Astrid Herzum, MD Dermatology Unit, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147 Genova, Italy Tel: +39-10-56362208, Fax: +39-10-56362700 E-mail: astridherzum@yahoo.it

No potential conflict of interest relevant to this article was reported.



© Korean Vaccine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disseminated life-threatening viral skin rash in a child with atopic dermatitis

We report the case of a toddler, with a history of mild atopic dermatitis (AD) since early infancy, presented to the Giannina Gaslini, a pediatric polyclinic hospital, 14 days after measles-mumpsrubella (MMR) vaccination, for the occurrence of a disseminated vesico-pustular rash, accompanied by general malaise, fever, restlessness, and anorexia. Eczema herpeticum (EH) was diagnosed clinically and confirmed by laboratory examinations. The exact pathogenesis of EH in AD is still debated and possibly involves an inter-play between altered cell-mediated and humoral immunity, failure to up-regulate antiviral proteins, and exposure of viral binding sites through the dermatitis and an epidermal barrier failure. We hypothesize that in this particular case, MMR vaccination might have played an additional important role in the alteration of innate immune response, facilitating the manifestation of herpes simplex virus type 1 in the form of EH.

Keywords: Atopic dermatitis, Eczema, Eczema herpeticum, Exanthema, Measles-mumpsrubella vaccine

Atopic dermatitis (AD) affects almost 20% of children worldwide, making it of the top medical issues to deal with as pediatricians and pediatric dermatologists [1].

As it is well known, AD may predispose to infectious complications, requiring prompt identification and referral to an AD specialist for ultimate diagnosis and therapeutic approach [1]. Among these, eczema herpeticum (EH), mainly caused by herpes simplex virus 1 (HVS-1), represents a disseminated life-threatening infection to which AD patients are prone. However, the exact pathogenesis of EH in AD is still debated and possibly involves an interplay between epidermal barrier failure, exposure of viral binding sites, and failure to up-regulate antiviral proteins [2,3].

Herein we present the case of a 14-month-old boy, with mild AD since early infancy, presented to the pediatric polyclinic hospital Giannina Gaslini for the occurrence of a disseminated vesico-pustular rash, accompanied by general malaise, fever, restlessness, and anorexia. Disease onset was reported 2 weeks after measles-mumps-rubella (MMR) vaccination, administered according to the Italian vaccination schedule, 3 days after having played in the sand with other kids on a sunny and hot weekend.

On physical examination, the patient was agitated, with a 37.1°C temperature, 118 bpm heart rate, 31 breaths/min respiratory rate, and with cervical lymphoadenomegalia. At clinical skin examination revealed disseminated, grouped, monomorphic outcomes of vesicles in the form of oozing erosions, and coalescing sero-hematic crusts at the erythematous base (Fig. 1). Lesions were generalized, especially evident in areas within reach of scratching, and remarkably intense in areas exposed to friction when crawling, as characteristic of atopic eczema (Fig. 2).

EH was diagnosed clinically and confirmed by laboratory examinations revealing elevated C-reactive protein (0.78 mg/dL), elevated large uncolored cells 5.5%, and by serological examinations revealing secondary herpes simplex virus type 1 (HSV-1) infection with positive immunoglobulin (Ig)G and IgM. The patient has been prescribed acyclovir 200 mg 4 times daily for 10 days and empirical antibiotic therapy with amoxicillin 500 mg in two doses for 10 days. A few days after, the mother reported clinical improvement, and at the 10th-day follow-up visit, the patient was normally active and lesions had resolved to leave hypopigmented macules.

Written informed consent was obtained for publication of the present case and of relative documentation, including photographic documentation.

AD is an immune-mediated inflammatory condition, believed to be caused by a combination of genes and external factors such as ecological influence, infections, and others, promoting the immune system to go into overdrive [1]. As a result of impaired skin barrier properties and altered cellmediated immunity, AD patients are susceptible to severe viral infections [1].

Possibly, eczema-induced epidermal spongiosis facilitates the binding and uptake of viruses, by exposing the desmosomal protein Nectin-1, a constituent of inter-keratinocytic zonulae adherentes, that was recently identified as a relevant HSV receptor in humans [3].

Also, AD patients, show low levels of natural killer (NK)cells and defective NK-cytotoxic activity, reducing antiviral defense [4,5]. Moreover, a recent study reported low interferon gamma (IFN- γ) and IFN- γ receptor gene expression in AD patients with EH, possibly contributing to the impaired immune response to HSV-1 [6].

We believe that in this particular case, MMR vaccination might have played an additional role in the alteration of the innate immune response, possibly demasking cutaneous binding sites for the virus, allowing the manifestation of HSV-1 in the form of EH [3].

Notably, in recent studies, MMR vaccination and measles infection have been associated with prolonged interleukin-4 (IL-4) elevation in blood plasma [7]. IL-4 is known to initiate T helper 2 cells development and allergic inflammation, as well as decreasing the expression of multiple genes associat-



Fig. 1. (A, B) Disseminated, grouped, monomorphic oozing erosions, and coalescing sero-hematic crusts, on erythematous base of shoulders, arms, and wrists. Written informed consent for the publication of this image was obtained from the patient.



Fig. 2. Coalescing crusts of the lower limbs, especially evident on areas characteristic for atopic eczema, as areas exposed to friction when crawling, such as the ankles and dorsal feet. Written informed consent for the publication of this image was obtained from the patient.

CLINICAL AND EXPERIMENTAL VACCINE RESEARCH

Astrid Herzum et al • Viral skin rash in an atopic child

ed with innate defense in AD, including the epidermal differentiation complex gene, regulating epidermal barrier function, leading to an impairment in the protective skin barrier function in AD, thus allowing superinfections to occur [7]. Especially, in atopic patients, failure to recognize EH can result in significant morbidity, implying the need for further studies to have a more in-depth understanding of resembling situations after MMR vaccination, which was sporadically associated with fever and cutaneous rashes [8]. The authors want to highlight that AD does not represent a contraindication to the administration of preventive vaccinations, as suggested by recent recommendations, yet advise individual monitoring of AD patients after vaccine administration [9].

Conclusively, this case emphasizes the importance of careful clinical evaluation of AD patients, not to overlook possibly life-threatening complications, which need prompt diagnosis and systemic therapy to prevent disease dissemination and shorten the course of infection.

ORCID

Astrid Herzum https://orcid.org/0000-0001-6373-8801 Corrado Occella https://orcid.org/0000-0001-5960-3808 Ehab Garibeh https://orcid.org/0000-0002-5611-2074 Lodovica Gariazzo https://orcid.org/0000-0001-7579-0121 Gianmaria Viglizzo https://orcid.org/0000-0001-7083-448X

References

1. Eichenfield LF, Stripling S, Fung S, Cha A, O'Brien A, Schachner LA. Recent developments and advances in atopic dermatitis: a focus on epidemiology, pathophysiology, and treatment in the pediatric setting. Paediatr Drugs 2022;24: 293-305.

- 2. Almoalem M, AlAlhareth I, Alomer H, et al. Extensive eczema herpeticum in a previously well child. Int J Emerg Med 2022;15:21.
- 3. Rerinck HC, Kamann S, Wollenberg A. Eczema herpeticum: pathogenesis and therapy. Hautarzt 2006;57:586-91.
- 4. Hodara E, Ong PY. The genetics of eczema herpeticum. Clin Rev Allergy Immunol 2022;63:390-7.
- 5. Kawakami Y, Ando T, Lee JR, et al. Defective natural killer cell activity in a mouse model of eczema herpeticum. J Allergy Clin Immunol 2017;139:997-1006.
- Leung DY, Gao PS, Grigoryev DN, et al. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response. J Allergy Clin Immunol 2011;127:965-73.
- Olesen AB, Juul S, Thestrup-Pedersen K. Atopic dermatitis is increased following vaccination for measles, mumps and rubella or measles infection. Acta Derm Venereol 2003;83:445-50.
- 8. Xiao YH, Chang SY, Bai S, et al. Immunogenicity and safety of a boost dose of measles, mumps, and rubella combined vaccine for 4-6 years old children. Zhonghua Liu Xing Bing Xue Za Zhi 2021;42:1086-91.
- 9. Martinez-Cabriales SA, Kirchhof MG, Constantinescu CM, Murguia-Favela L, Ramien ML. Recommendations for vaccination in children with atopic dermatitis treated with dupilumab: a consensus meeting, 2020. Am J Clin Dermatol 2021;22:443-55.